Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlormadinone is a synthetic progestin and antiandrogen used primarily in combination with estrogens for oral combined hormonal contraceptive therapy. It acts as an agonist of the progesterone receptor and as an antagonist of the androgen receptor. Its main clinical uses are in contraception, menopausal hormone therapy, and treatment of gynecological disorders. Chlormadinone is also used to treat androgen-dependent conditions such as acne and hirsutism in women and benign prostatic hyperplasia or prostate cancer in men. The drug suppresses ovulation by inhibiting gonadotropin secretion, thickens cervical mucus to prevent sperm penetration, reduces endometrial thickness, and exhibits moderate antiandrogenic activity[1][3][8]. It is available both alone (in some countries) or more commonly as its acetate ester form (chlormadinone acetate), often combined with ethinylestradiol for contraception.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlormadinone.